Search

  • HOME
  • Search
Original Articles
Efficacy of Roflumilast in Bronchiectasis Patients with Frequent Exacerbations: A Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial
Siwasak Juthong, Pattaraporn Panyarath
Received March 23, 2021   Accepted August 1, 2021   Published online August 3, 2021   
DOI: https://doi.org/10.4046/trd.2021.0051    [Epub ahead of print]
PDFPDF    
COPD
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study
Hyonsoo Joo, Deokjae Han, Jae Ha Lee, Chin Kook Rhee
Tuberc Respir Dis. 2018;81(4):299-304.   Published online June 19, 2018
Full textFull text    PubreaderPubReader    CrossRef-TDMCrossref - TDM    PDFPDF    
The Phosphodiesterase 4 Inhibitor Roflumilast Protects against Cigarette Smoke Extract-Induced Mitophagy-Dependent Cell Death in Epithelial Cells
Sun Young Kyung, Yu Jin Kim, Eun Suk Son, Sung Hwan Jeong, Jeong-Woong Park
Tuberc Respir Dis. 2018;81(2):138-147.   Published online March 13, 2018
Full textFull text    PubreaderPubReader    CrossRef-TDMCrossref - TDM    PDFPDF    

Tuberculosis and
Respiratory Diseases

Print ISSN: 1738-3536
Online ISSN: 2005-6184



ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2021 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next